Medical

Immunotherapy has been a very important treatment in recent years, with many patients in lung cancer, malignant melanoma and many other cancers experiencing dramatic improvements in prognosis with this cutting-edge therapy. In pancreatic cancer, however, progress in immunotherapy has been very slow and its effectiveness has been extremely limited.

Afamitresgene Autoleucel, also known as Afami-cel or ADP-A2M4, is a novel TCR-T cell immunotherapy that has produced durable and promising results in patients with advanced synovial sarcoma or mucinous/round cell liposarcoma

According to data from a phase 2 trial, the new treatment Tovorafenib resulted in significant tumour shrinkage in 64% of patients with low-grade gliomas in children, a clinical benefit rate of 91%.

In recommendations released on 2 February 2023, the National Comprehensive Cancer Network (NCCN) recommends that doctors consider neratinib for patients with HER2-negative metastatic breast cancer, regardless of their estrogen receptor status.

Can patients with bridge onychiasis and hypothyroidism have normal childbearing?

Results from a pivotal phase 3 trial show that the PD-1 therapy Keytruda, in combination with chemotherapy, significantly improves survival in patients with advanced gastric cancer and has a favorable safety profile. Patients benefited regardless of their PD-L1 expression.

Pfizer's new treatment, Elranatamab, has received Breakthrough Therapy designation from the FDA for the treatment of patients with relapsed or refractory multiple myeloma. Data from the trial showed a patient efficacy rate of 61.0% and that once the therapy is effective, efficacy is maintained for more than six months in over 90% of patients!

New research by japanese scientists has found that

Recent findings show that the use of cutting-edge immune checkpoint inhibitor therapy (referred to as immunotherapy in this article) has increased rapidly over the past decade in the population of patients with advanced non-small cell lung cancer (NSCLC), but the survival benefit is more pronounced in younger people than in older people, who have limited survival benefit with this therapy.

Dry eye after excimer surgery is a common problem. The main reason for the occurrence of dry eye after surgery is that during excimer surgery, the production of corneal flap and the cutting of matrix cut off the sensory nerve of part of the cornea, reducing the sensory and neurotrophic functions of the cornea, leading to the reduction of reflective tear secretion and the number of blinks, which leads to the reduction of the amount of tear secretion and the stability of the tear film. The study found that the corneal nerve after surgery can be restored to the preoperative level after 6-9 months of regeneration and repair. Therefore, dry eye may be obvious at the early stage after surgery, but it will gradually reduce with corneal repair until it returns to normal.